2 days ago
Pioneering new drug could replace aggressive cancer therapies
A new medicine, KCL-HO-1i, has been developed to improve cancer treatment by enhancing the effectiveness of chemotherapy.
The drug works by dismantling a crucial defence mechanism used by tumours, specifically targeting the heme oxygenase-1 (HO-1) protein produced by macrophages that shield tumours.
Initial trials conducted on mice demonstrated that KCL-HO-1i made chemotherapy-resistant tumours responsive to treatment.
Researchers at King's College London, who developed the drug, are hopeful for human trials to begin within two years.
This new medicine could potentially serve as a valuable companion drug to chemotherapy, sparing patients from more aggressive interventions.
